NCIC CLINICAL TRIALS GROUP
HEAD AND NECK

DISEASE SITE WORKING GROUP MEETING AGENDA

DELTA CHELSEA HOTEL, TORONTO, ON

ROOM: STEVENSON

APRIL 28TH, 2013 – 8:00 AM – 12:00 PM

CO-CHAIRS : B. O’SULLIVAN & R. GILBERT

CME Credits:
Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen’s University.

Learning Objectives:
− To understand and apply new clinical trial methodologies in the field of clinical research in head and neck cancer
− To review relevant recent head and neck cancer data that may guide clinical trials in head and neck cancer
− To discuss available information and analysis plans relevant to recent clinical trials in head and neck cancer performed by the NCIC CTG
− To appreciate and discuss logistic issues applicable to clinical trials in head and neck cancer, with particular focus on quality assurance

8:00 am Welcome B. O’Sullivan
8:05 am HN.5 publication update W. Parulekar
8:10 am HN.6 update: L. Siu /J. Waldron /W. Parulekar

➢ Study timelines
➢ Analysis plans
➢ Secondary Analysis:
  - Swallowing VFS Sub-study R. Martino
  - Correlative Sciences Questionnaire G. Liu /S.Cuffe
  - Pharmacogenetic and cisplatin ototoxicity J. Monzon /G. Liu

continued on next page ...
**Previous proposals**

8:40 am  Background and Rationale for Randomized trials addressing 2 HPV(+) subgroups  
B. O’Sullivan

8:55 am  Accelerated Radiotherapy alone in Favorable HPV(+) SCCHN  
B. O’Sullivan/J. Waldron

9:15 am  Induction Chemotherapy followed by Accelerated Radiotherapy Alone in Unfavorable HPV(+) SCCHN  
B. O’Sullivan/E. Winquist

9:35 am  End-points and potential sample sizes  
B. O’Sullivan/J. Waldron/E. Winquist

9:50 am  Radiotherapy QA for Trials  
J. Waldron

10:05 am  Coffee break

**New proposals**

10:20 am  Accelerated Radiotherapy alone in HPV related locally advanced oropharyngeal cancer  
S. Kader

10:40 am  Dosimetric planning feasibility for HPV (-) locally advanced patients who are not candidates for chemotherapy  
L. Eapen

**Other Cooperative Group Head and Neck Trial under Development involving Canadian centre(s)**

11:00 am  Intergroup Study (EORTC-1219-ROG-HNCG DAHANCA-29)  
B. O’Sullivan

An open label randomized multicenter study of accelerated fractionated chemo-radiotherapy with or without the hypoxic radiosensitizer nimorazole (Nimoral), using a 15 gene signature for hypoxia in the treatment of HPV/p16 negative squamous cell carcinoma of the head and neck.

**Strategic Directions for the NCIC CTG Head and Neck Working Group**

11:20 am  Targeting PI3K/PTEN in SCCHN  
Nichols/Palma/Winquist; Siu/Waldron/O’Sullivan

11:40 am  Pragmatic phase III vs IND/molecular characterization trials  
B. O’Sullivan/ W. Parulekar

12:00 am  Meeting Adjourned